Skip to main content
BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.50
-0.07 (-0.82%)
At close: Mar 5, 2026, 4:00 PM EST
8.46
-0.04 (-0.47%)
Pre-market: Mar 6, 2026, 8:40 AM EST

BioCryst Pharmaceuticals Revenue by Segment
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Orladeyo
601.84M 574.34M 531.59M 483.04M 437.66M 404.36M 373.72M 346.44M
Orladeyo Growth
37.51% 42.04% 42.24% 39.43% 34.26% 32.21% 30.61% 28.15%
Other
273.00M 25.47M 25.92M 20.45M 13.05M 8.22M 8.51M 8.95M
Other Growth
1,991.62% 209.82% 204.45% 128.43% 140.72% -29.82% -58.49% -53.71%

Revenue by Type
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Product
623.15M 593.30M 551.63M 497.18M 442.67M 404.06M 373.29M 345.80M
Product Growth
40.77% 46.83% 47.78% 43.78% 36.33% 29.50% 23.63% 20.77%
Collaborative and Other
251.69M 6.52M 5.88M 6.30M 8.04M 8.52M 8.95M 9.59M
Collaborative and Other Growth
3,028.87% -23.43% -34.31% -34.31% 19.77% 53.86% 90.65% 186.19%

Revenue by Geography
Period Ending Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
United States
548.78M 509.03M 470.58M 426.15M 385.96M 358.41M 330.57M 307.48M
United States Growth
42.19% 42.02% 42.36% 38.60% 33.85% 31.50% 28.43% 26.39%
Outside of US
53.06M 65.32M 61.00M 56.88M 51.70M 45.94M 43.15M 38.97M
Outside of US Growth
2.63% 42.17% 41.37% 45.98% 37.39% 38.00% 50.14% 43.94%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.